Clinical trial
Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD
NCT04458103 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Not applicable
- Overall status
- Terminated
- Start date
- May 12, 2020
- Completion date
- June 1, 2023
- Enrollment
- 161 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.